Acute nicotinamide riboside supplementation increases human cerebral NAD+ levels in vivo.
Saved in:
| Title: | Acute nicotinamide riboside supplementation increases human cerebral NAD+ levels in vivo. |
|---|---|
| Authors: | Nanga, Ravi Prakash Reddy1 (AUTHOR), Wiers, Corinde E.2 (AUTHOR), Elliott, Mark A.1 (AUTHOR), Wilson, Neil E.1 (AUTHOR), Liu, Fang3 (AUTHOR), Cao, Quy3 (AUTHOR), Swago, Sophie4 (AUTHOR), Jacobs, Paul S.4 (AUTHOR), Armbruster, Ryan4 (AUTHOR), Reddy, Damodara1 (AUTHOR), Baur, Joseph A.5 (AUTHOR), Witschey, Walter R.1 (AUTHOR), Detre, John A.6 (AUTHOR), Reddy, Ravinder1 (AUTHOR) krr@pennmedicine.upenn.edu |
| Source: | Magnetic Resonance in Medicine. Dec2024, Vol. 92 Issue 6, p2284-2293. 10p. |
| Subjects: | Nicotinamide, Brain function localization, Adenine, Dietary supplements, Ingestion |
| Abstract: | Purpose: The purpose of this study was to determine the effect of acute nicotinamide riboside (NR) supplementation on cerebral nicotinamide adenine dinucleotide (NAD+) levels in the human brain in vivo by means of downfield proton MRS (DF 1H MRS). Methods: DF 1H MRS was performed on 10 healthy volunteers in a 7.0 T MRI scanner with spectrally selective excitation and spatially selective localization to determine cerebral NAD+ levels on two back‐to‐back days: once after an overnight fast (baseline) and once 4 h after oral ingestion of nicotinamide riboside (900 mg). Additionally, two more baseline scans were performed following the same paradigm to assess test–retest reliability of the NAD+ levels in the absence of NR. Results: NR supplementation increased mean NAD+ concentration compared to the baseline (0.458 ± 0.053 vs. 0.392 ± 0.058 mM; p < 0.001). The additional two baseline scans demonstrated no differences in mean NAD+ concentrations (0.425 ± 0.118 vs. 0.405 ± 0.082 mM; p = 0.45), and no difference from the first baseline scan (F(2, 16) = 0.907; p = 0.424). Conclusion: These preliminary results confirm that acute NR supplementation increases cerebral NAD+ levels in healthy human volunteers and shows the promise of DF 1H MRS utility for robust detection of NAD+ in humans in vivo. [ABSTRACT FROM AUTHOR] |
| Copyright of Magnetic Resonance in Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Purpose: The purpose of this study was to determine the effect of acute nicotinamide riboside (NR) supplementation on cerebral nicotinamide adenine dinucleotide (NAD+) levels in the human brain in vivo by means of downfield proton MRS (DF 1H MRS). Methods: DF 1H MRS was performed on 10 healthy volunteers in a 7.0 T MRI scanner with spectrally selective excitation and spatially selective localization to determine cerebral NAD+ levels on two back‐to‐back days: once after an overnight fast (baseline) and once 4 h after oral ingestion of nicotinamide riboside (900 mg). Additionally, two more baseline scans were performed following the same paradigm to assess test–retest reliability of the NAD+ levels in the absence of NR. Results: NR supplementation increased mean NAD+ concentration compared to the baseline (0.458 ± 0.053 vs. 0.392 ± 0.058 mM; p < 0.001). The additional two baseline scans demonstrated no differences in mean NAD+ concentrations (0.425 ± 0.118 vs. 0.405 ± 0.082 mM; p = 0.45), and no difference from the first baseline scan (F(2, 16) = 0.907; p = 0.424). Conclusion: These preliminary results confirm that acute NR supplementation increases cerebral NAD+ levels in healthy human volunteers and shows the promise of DF 1H MRS utility for robust detection of NAD+ in humans in vivo. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 07403194 |
| DOI: | 10.1002/mrm.30227 |
